




The relative strengths and weaknesses of Diamedica Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Diamedica Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 170% points. The greatest weakness of Diamedica Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 348%, being 119% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	60,629
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,132
Liabilities, Non-Current	128
Other Assets	597
Other Compr. Net Income	27
Other Expenses	28
Other Liabilities	0
Other Net Income	1,659
Other Revenues	0
Property and Equipment	145
Research and Development	24,614
Selling, General and Administrative Expense	9,783

Output Variable	Value in 1000 USD
Assets	61,371
Liabilities	5,260
Expenses	34,425
Revenues	0
Stockholders Equity	56,111
Net Income	-32,766
Comprehensive Net Income	-32,752
BaseVar	51,371
ECR before Limited Liability	269%
Economic Capital Ratio	348%